期刊
JOURNAL OF PATHOLOGY
卷 232, 期 2, 页码 142-150出版社
WILEY
DOI: 10.1002/path.4280
关键词
triple-negative breast cancer; EGFR; FGFR; TP53; WEE1; AR; VEGFR; INPP4B; genomic instability; subtypes; TNBCtype; PHGDH; LDHB; INPP4B; PTEN; PIK3CA; TP53; basal-like; therapy
资金
- Breast Cancer Specialized Program of Research Excellence (SPORE) [2P50CA098131]
- American Cancer Society [119807-PF-10-226-01-TBG]
- Susan G. Komen for the Cure [SAC110030, CCR13262005]
- NATIONAL CANCER INSTITUTE [P50CA098131] Funding Source: NIH RePORTER
Triple-negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that respond differentially to chemotherapy and targeted agents. The absence of high-frequency molecular alterations and a limited number of known biomarkers have limited the development of therapeutic strategies for the disease. Herein, we summarize the results of the first round of targeted therapy approaches in TNBC and discuss new preclinical strategies. Common themes emerge from the proposed strategies, such as the use of biomarkers to identify tumours with genomic instability, targeting adapted molecular states resulting from tumour suppressor loss, and targeting altered metabolic pathways. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据